| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Liwu Fu | |
| Sainan An | |||
| P2860 | cites work | Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. | Q52673134 |
| Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis. | Q52725933 | ||
| Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase using PROTAC-mediated Degradation. | Q54977556 | ||
| Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. | Q55052388 | ||
| Greasy tags for protein removal | Q59095262 | ||
| Degradation of target protein in living cells by small-molecule proteolysis inducer | Q75325862 | ||
| Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool | Q81377065 | ||
| Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma | Q88182734 | ||
| PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies | Q89014299 | ||
| Identification of a primary target of thalidomide teratogenicity | Q24302178 | ||
| Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers | Q24611043 | ||
| Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 | ||
| The dynamic nature of the kinome | Q26852588 | ||
| Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities | Q27640584 | ||
| Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α | Q27674529 | ||
| Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction | Q27677509 | ||
| Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation | Q28513426 | ||
| DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation | Q28830958 | ||
| Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein | Q29615928 | ||
| Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals). | Q30313275 | ||
| Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. | Q33942731 | ||
| Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation | Q34083015 | ||
| Small-molecule inhibitors of protein-protein interactions: progressing toward the reality | Q34263719 | ||
| Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators | Q34294692 | ||
| Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. | Q34478968 | ||
| Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. | Q34479551 | ||
| HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins | Q34480529 | ||
| Catalytic in vivo protein knockdown by small-molecule PROTACs. | Q34480735 | ||
| Pharmacological targeting of the pseudokinase Her3 | Q34514043 | ||
| Induced protein degradation: an emerging drug discovery paradigm | Q34545841 | ||
| Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer | Q34610455 | ||
| Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway | Q34662199 | ||
| Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics | Q34815558 | ||
| E3 ubiquitin ligases as cancer targets and biomarkers | Q35082710 | ||
| Nature Biotechnology's academic spinouts of 2013. | Q35146529 | ||
| Small-molecule modulation of Ras signaling | Q35188280 | ||
| Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging | Q35666096 | ||
| Small-Molecule PROTACS: New Approaches to Protein Degradation | Q35891557 | ||
| In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs). | Q36268420 | ||
| Structural basis of PROTAC cooperative recognition for selective protein degradation | Q36306106 | ||
| The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies | Q36584337 | ||
| EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. | Q37021792 | ||
| PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer | Q37065079 | ||
| Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds | Q38673230 | ||
| Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. | Q38710711 | ||
| Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL. | Q38817737 | ||
| Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. | Q39102535 | ||
| Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy. | Q39406339 | ||
| Use of PROTACS as molecular probes of angiogenesis | Q39464707 | ||
| Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. | Q39574650 | ||
| Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. | Q39718603 | ||
| Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer | Q39939428 | ||
| Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators | Q40073529 | ||
| Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras. | Q40347061 | ||
| Chemical genetic control of protein levels: selective in vivo targeted degradation | Q40574972 | ||
| Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells | Q41190385 | ||
| Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. | Q41816118 | ||
| Inhibitor mediated protein degradation. | Q42178606 | ||
| Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation. | Q42217007 | ||
| Androgen receptor gene mutation, rearrangement, polymorphism. | Q42738421 | ||
| Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. | Q42882393 | ||
| Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. | Q45858607 | ||
| Development of a Small Hybrid Molecule That Mediates Degradation of His-Tag Fused Proteins. | Q45867253 | ||
| Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands. | Q45868652 | ||
| Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. | Q47411643 | ||
| A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. | Q47411648 | ||
| The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study | Q47411655 | ||
| Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. | Q48100900 | ||
| Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1. | Q48151643 | ||
| Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. | Q48195544 | ||
| Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. | Q48265414 | ||
| BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells | Q50433449 | ||
| Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). | Q50932257 | ||
| The dTAG system for immediate and target-specific protein degradation. | Q52340959 | ||
| Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). | Q52600736 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | targeted therapy | Q492646 |
| biomedical investigative technique | Q66648976 | ||
| small molecule libraries | Q50573438 | ||
| P304 | page(s) | 553-562 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | EBioMedicine | Q24912341 |
| P1476 | title | Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs | |
| P478 | volume | 36 |
| Q61809000 | Bivalent Ligands for Protein Degradation in Drug Discovery |
| Q92073027 | Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs |
| Q89810816 | Characterization of cereblon-dependent targeted protein degrader by visualizing the spatiotemporal ternary complex formation in cells |
| Q89823393 | Degradation of proteins by PROTACs and other strategies |
| Q111442197 | Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins |
| Q92453516 | Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss |
| Q96128046 | Identification of a potent and selective covalent Pin1 inhibitor |
| Q92191065 | Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments |
| Q92647353 | Novel immunomodulatory drugs and neo-substrates |
| Q90186445 | PROTACs- a game-changing technology |
| Q92310282 | PROTACs: great opportunities for academia and industry |
| Q90461512 | Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications |
| Q89462180 | Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery |
| Q92578345 | SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines |
| Q100407251 | Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin |
| Q89865609 | Targeting the SAGA and ATAC Transcriptional Coactivator Complexes in MYC-Driven Cancers |
Search more.